Small-Molecule Inhibition of KRAS through Conformational Selection

[Image: see text] Mutations in KRAS account for about 20% of human cancers. Despite the major progress in recent years toward the development of KRAS inhibitors, including the discovery of covalent inhibitors of the G12C KRAS variant for the treatment of non-small-cell lung cancer, much work remains...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagba, Cynthia V., Gupta, Amit K., Gorfe, Alemayehu A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468774/
https://www.ncbi.nlm.nih.gov/pubmed/37663463
http://dx.doi.org/10.1021/acsomega.3c04013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468774/
https://www.ncbi.nlm.nih.gov/pubmed/37663463
http://dx.doi.org/10.1021/acsomega.3c04013

Ejemplares similares